

CSD/NSE&BSE/2025-26
September 18, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE

Dear Sir/ Madam,

Sub: Disclosure under the SEBI (Prohibition of Insider Trading) Regulations, 2015

We forward herewith disclosure received from Jusmiral Holdings Limited, promoter of the Company, under the SEBI (Prohibition of Insider Trading) Regulation, 2015 with respect to sale of shares of the Company.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com



September 18, 2025

To

The Company Secretary and Compliance Officer
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited)
202, A-Wing, Galaxy Towers,
Plot No. 1, Hyderabad Knowledge City,
TSIIC, Raidurg, Hyderabad – 500081

Dear Sir,

Sub: Disclosure of sale of shares under Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (“Insider Trading Regulations”)

We enclose herewith a disclosure pursuant to Regulation 7(2) of the Insider Trading Regulations.


This disclosure is consequent to a sale of 3,41,48,000 shares by Jusmiral Holdings Limited on September 18, 2025, and, Jusmiral Holdings Limited intends for the proceeds of the sale to be utilized, primarily, for the purposes of part payment of the borrowings under the Notes Purchase Agreement, disclosures in respect of which have been made on May 9, 2025 by Jusmiral Holdings Limited under Regulations 31(1) and 31(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

This is submitted for your information and records.

Thanking you,

Yours faithfully,

For Jusmiral Holdings Limited



Name: Christodoulos Patsalides
Designation: Director

SEBI (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7 (2) read with Regulation 6(2) – Continual Disclosure]

Name of the company: Cohance Lifesciences Limited

ISIN of the company: L24299MH2018PLC422236

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN, & address with contact nos.	Category of Person (Promoter / member of the promoter group/ designated person/ Directors/ immediate relative to/others etc.)	Securities held prior to acquisition/ disposal		Securities acquired /Disposed				Securities held post acquisition/ disposal		Date of allotment- advice - acquisition-of- shares/- disposal of shares, specify		Date of intimation to company	Mode of acquisition- n - /disposal (on market/ public/ rights/ preferential offer/ off market/ Inter-se transfer, ESOPs, etc.)	Exchange on which the trade was executed
		Type of securities (For eg. – Shares Warrants, Convertible Debentures , Rights entitlements etc.)	No. and % of share holding	Type of securities (For eg. – Shares, Warrants, Convertible Debentures, Rights entitlement , etc.)	No.	Value	Transaction Type (Purchase/ sale Pledge / Revocation/ Invocation/ Others- please specify)	Type of securities (For eg. – Shares, Warrants, Convertible Debentures, Rights entitlement , etc.)	No. and % of shareholding	From	To			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Jusmiral Holdings Limited PAN: AAECJ6837B	Promoter	Shares	12,65,38,578 33.08%	Shares	3,41,48,000	3093,80,88,000	Sale	Shares	9,23,90,578 24.15%	September 18, 2025	September 18, 2025	September 18, 2025	On market	National Stock Exchange of India Limited

Address: Kennedy 23, Nicosia, Post Code – 1075, Cyprus Contact No. +357 22007960														
---	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Note: (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

(ii) Value of transaction excludes taxes/brokerage/any other charges

Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Trading in derivatives (Specify type of contract, Futures or Options etc.)						Exchange on which the trade was executed
Type of contract	Contract specifications	Buy		Sell		
		Notional Value	Number of units (contracts * lot size)	Notional Value	Number of units (contracts * lot size)	
16	17	18	19	20	21	22
Nil	Nil	Nil	Nil	Nil	Nil	Nil

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

Name & Signature:
For Jusmiral Holdings Limited

Name: Christodoulos Patsalides

Designation: Director

Date: 18 September 2025

Place: Cyprus